Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations
On February 12, Goldman Sachs raised its price target on Royalty Pharma plc (NASDAQ:RPRX) to $51 from $45 and maintained a Buy rating after strong Q4 results.
Royalty Pharma Plc (RPRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 11,740,594 | $453,656,552 | -2% | 0.69% |
| 2. | Citadel Investment Group Ken Griffin | 5,273,865 | $203,782,144 | +1237% | 0.03% |
| 3. | Patient Capital Management Samantha Mclemore | 3,333,675 | $128,813,194 | +7% | 4.97% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,313,265 | $128,024,560 | +1% | 0.07% |
| 5. | VGI Partners Robert M. P. Luciano | 2,640,708 | $102,036,956 | +85% | 5.88% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.51 | 130,000 | $3,836,768.00 | 600,000 | 2023-06-28 | Filing | |
| $32.78 | 45,000 | $1,474,902.00 | 470,000 | 2023-06-13 | Filing | |
| $33.00 | 45,000 | $1,484,946.00 | 425,000 | 2023-06-12 | Filing | |
| $32.25 | 150,000 | $4,837,440.00 | 380,000 | 2023-05-24 | Filing | |
| $32.94 | 69,612 | $2,293,095.85 | 230,000 | 2023-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.01 | 583 | $27,409.34 | 45,761 | 2026-03-02 | Filing | |
| $46.67 | 1,292 | $60,303.71 | 46,344 | 2026-03-02 | Filing | |
| $47.01 | 10,429 | $490,314.22 | 98,748 | 2026-03-02 | Filing | |
| $46.67 | 22,487 | $1,049,506.52 | 109,177 | 2026-03-02 | Filing | |
| $45.32 | 1,875 | $84,968.44 | 47,636 | 2026-02-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 55,274,069 | $2,135,790,095 | 0.13% | |
| 2. | 31,104,309 | $1,201,870,500 | 0.19% | |
| 3. | 26,272,308 | $1,015,161,996 | 0.05% | |
| 4. | 26,188,692 | $1,011,931,068 | 0.02% | |
| 5. | 17,008,768 | $657,218,795 | 0.55% |
News See All
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule
Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now.
12 Dirt Cheap Stocks to Buy Now
On February 23, Pierre Ouimet, head investment strategist at UBS Canada, joined BNN Bloomberg to discuss the markets and provide a spotlight on undervalued sectors.
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here's Why
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best cheap biotech stocks to buy now.
12 Cheap Biotech Stocks to Buy Now
On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
11 Best Low Priced Growth Stocks to Buy Right Now
Low-priced growth stocks, specifically those combining a low forward P/E ratio with strong or accelerating Earnings Per Share (EPS), offer a compelling blend of value and momentum.
Royalty Pharma plc (NASDAQ:RPRX) Q4 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Royalty Pharma Fourth Quarter Earnings Conference Call.
UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) - Here's Why
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best healthcare stocks under $50 to invest in.
12 Best Healthcare Stocks Under $50 to Invest In
On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage.
Jim Cramer Shared His Takes on These 16 Stocks
On the surface, the stock market seems totally binary, dancing to the tune of a president who likes to take the averages into his own hands and raise or lower them depending upon the circumstance.
Hedge Fund Resource Center